Supernus Pharmaceuticals reported $0 in Interest Expense on Debt for its fiscal quarter ending in December of 2024.


Interest Expense On Debt Change Date
Abbott USD 50M 1000K Jun/2025
ANI Pharmaceuticals USD 5.44M 46K Jun/2025
Aurora Cannabis CAD 1.78M 491K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Canopy Growth CAD 9.74M 7.03M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Eisai 916M 174M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Novo Nordisk 4.96B 225M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Pfizer USD 654M 0 Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
United Therapeutics USD 7.3M 1.2M Jun/2025
Xeris Pharmaceuticals USD 7.36M 343K Jun/2025